secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001213900-23-039083
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Q2 FY2023 net loss $10.5M ($0.07/share); Halo-Lido Phase 2b topline expected Q2 2023
--------------------------------------------------------------------------------

- Net loss of $10.5M ($0.07 per share) for fiscal Q2 ended March 31, 2023, vs $7.6M ($0.05) a year ago.
- Cash $29.1M as of March 31, 2023; raised $15M in May 2023 registered direct offering, extending runway through May 2024.
- Halo-Lido Phase 2b hemorrhoid trial completed; topline results expected by end of calendar Q2 2023.
- Mino-Lok Phase 3 trial at 85 of 92 required events; enrollment ongoing aiming for completion in 2023.
- I/ONTAK BLA under FDA review with PDUFA date July 28, 2023; spinoff preparation continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/0001213900-23-039083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390023039083/ea178475-8k_citiuspharma.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-039083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer